Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Acorda Therapeutics Inc : Acorda Presents New Data on Diazepam Nasal Spray at 67th Annual Meeting of American Epilepsy Society

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2013 | 01:01pm CEST

Study found Diazepam Nasal Spray maintained consistent pharmacokinetic profile when administered during or immediately after seizure

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics (PK) whether the drug was administered during or immediately after a seizure. These data were presented at the 67th Annual Meeting of the American Epilepsy Society, in Washington, D.C. Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.

"In this study, some patients received a dose of Diazepam Nasal Spray while having a seizure, while others received the dose after their seizure activity had ceased," said Adrian Rabinowicz, M.D., FAAN, Acorda's Senior Vice President of Clinical Development and Medical Affairs. "The results suggest that delivery of Diazepam Nasal Spray was unaffected by the timing of dosage relative to seizure activity. It is critical for a person with epilepsy who experiences cluster seizures that treatment be administered as soon as possible after a cluster is recognized, in order to prevent additional seizure activity."

This multicenter, open-label study was conducted in adults admitted to an epilepsy monitoring unit for evaluation and management of epilepsy. Of the 30 patients who completed the study, 10 were dosed during a seizure, while the other 20 patients were dosed after their seizure activity had ceased. Plasma concentrations of diazepam were measured for a period of up to 12 hours following the dose.

The overall safety and tolerability of Diazepam Nasal Spray in this study was consistent with systemic diazepam exposure established with other diazepam products. The most common local adverse events were related to the nasal route of delivery; most adverse events were mild and transient, and resolved within a day. These local events were an altered sense of taste and nasal discomfort, experienced by 26% and 23% of study subjects respectively.

Other data from this study were previously presented at the 30th biennial International Congress of the International League Against Epilepsy and International Bureau for Epilepsy.

Acorda has submitted a New Drug Application for Diazepam Nasal Spray to the U.S. Food and Drug Administration (FDA) and will rely upon the FDA's previous findings of safety and efficacy for diazepam rectal gel.

About Epilepsy and Cluster Seizures/Acute Repetitive Seizures

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Seizures are symptoms of abnormal brain activity, and occur when a brief, strong surge of electrical activity affects part or all of the brain.

Of the approximately 2.75 million people in the United States with epilepsy, it is estimated that about 175,000 experience cluster seizures. Cluster seizures, also known as acute repetitive seizures, are characterized by recognizable, recurring episodes of seizure clusters.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.

Acorda markets three FDA-approved therapies including: AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company's website at: www.acorda.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Diazepam Nasal Spray or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Diazepam Nasal Spray or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACORDA THERAPEUTICS INC
07/27 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) reported earnings of $0.29 per share m..
07/27 ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Results of Operations and ..
07/27 ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
07/27 ACORDA THERAPEUTICS : reports 2Q loss
07/27 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Second Quarter ..
07/13 ACORDA THERAPEUTICS : Second Quarter 2017 Update Webcast/Conference Call Schedul..
07/06 ACORDA THERAPEUTICS : Submits New Drug Application to U.S. Food and Drug Adminis..
07/06 Stocks Under Scanner in the Biotech Space — Achillion Pharma, Kite Phar..
06/29 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Other Events
06/29 ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
More news
News from SeekingAlpha
07/27 Acorda Investors Are Holding Their Breath
07/27 Acorda Therapeutics misses by $0.19, misses on revenue
07/26 Notable earnings before Thursday?s open
07/11 Acorda's Pipeline Has Potential
06/27 Kala Pharmaceuticals Files For $86 Million IPO
Financials ($)
Sales 2017 568 M
EBIT 2017 79,2 M
Net income 2017 34,3 M
Debt 2017 184 M
Yield 2017 -
P/E ratio 2017 29,73
P/E ratio 2018 278,21
EV / Sales 2017 2,11x
EV / Sales 2018 2,30x
Capitalization 1 013 M
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 27,7 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC15.43%1 052
AMGEN17.74%129 349
CELGENE CORPORATION15.90%107 559
GILEAD SCIENCES4.68%96 946
REGENERON PHARMACEUTICALS40.46%54 807
VERTEX PHARMACEUTICALS112.01%40 703